- Previous Close
40.36 - Open
40.89 - Bid 29.82 x 200
- Ask 52.35 x 200
- Day's Range
40.47 - 42.00 - 52 Week Range
15.85 - 60.90 - Volume
657,566 - Avg. Volume
713,839 - Market Cap (intraday)
2.435B - Beta (5Y Monthly) 1.76
- PE Ratio (TTM)
-- - EPS (TTM)
-3.82 - Earnings Date Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
53.09
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
www.twistbioscience.com919
Full Time Employees
September 30
Fiscal Year Ends
Sector
Industry
Recent News: TWST
View MorePerformance Overview: TWST
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TWST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TWST
View MoreValuation Measures
Market Cap
2.44B
Enterprise Value
2.23B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.12
Price/Book (mrq)
4.96
Enterprise Value/Revenue
7.56
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-74.63%
Return on Assets (ttm)
-16.39%
Return on Equity (ttm)
-38.36%
Revenue (ttm)
295.21M
Net Income Avi to Common (ttm)
-220.31M
Diluted EPS (ttm)
-3.82
Balance Sheet and Cash Flow
Total Cash (mrq)
289.42M
Total Debt/Equity (mrq)
17.75%
Levered Free Cash Flow (ttm)
-25.09M
Research Analysis: TWST
View MoreCompany Insights: TWST
TWST does not have Company Insights